Literature DB >> 34582425

Association of Catecholamine Dose, Lactate, and Shock Duration at Vasopressin Initiation With Mortality in Patients With Septic Shock.

Gretchen L Sacha1, Simon W Lam1, Lu Wang1,2, Abhijit Duggal3, Anita J Reddy3, Seth R Bauer1.   

Abstract

OBJECTIVES: To determine the association of catecholamine dose, lactate concentration, and timing from shock onset at vasopressin initiation with in-hospital mortality.
DESIGN: Retrospective, observational study using segmented and multivariable logistic regression to evaluate the associations of catecholamine dose, lactate concentration, and timing from shock onset at vasopressin initiation with in-hospital mortality.
SETTING: Multiple hospitals within the Cleveland Clinic Health System. PATIENTS: Adult patients who met criteria for septic shock based on the U.S. Centers for Disease Control and Prevention Adult Sepsis Event definition.
INTERVENTIONS: All patients received continuous infusion vasopressin as an adjunct to catecholamine vasopressors.
MEASUREMENTS AND MAIN RESULTS: In total, 1,610 patients were included with a mean Acute Physiology and Chronic Health Evaluation III 109.0 ± 35.1 and Sequential Organ Failure Assessment 14.0 ± 3.5; 41% of patients survived the hospital admission. At the time of vasopressin initiation, patients had median (interquartile range) lactate concentration 3.9 mmol/L (2.3-7.2 mmol/L), norepinephrine-equivalent dose 25 µg/min (18-40 µg/min), and 5.3 hours (2.1-12.2 hr) elapsed since shock onset. The odds of in-hospital mortality increased 20.7% for every 10 µg/min increase in norepinephrine-equivalent dose up to 60 µg/min at the time of vasopressin initiation (adjusted odds ratio, 1.21 [95% CI, 1.09-1.34]), but no association was detected when the norepinephrine-equivalent dose exceeded 60 µg/min (adjusted odds ratio, 0.96 [95% CI, 0.84-1.10]). There was a significant interaction between timing of vasopressin initiation and lactate concentration (p = 0.02) for the association with in-hospital mortality. A linear association between increasing in-hospital mortality was detected for increasing lactate concentration at the time of vasopressin initiation, but no association was detected for time elapsed from shock onset.
CONCLUSIONS: Higher norepinephrine-equivalent dose at vasopressin initiation and higher lactate concentration at vasopressin initiation were each associated higher in-hospital mortality in patients with septic shock who received vasopressin.
Copyright © 2022 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34582425     DOI: 10.1097/CCM.0000000000005317

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   9.296


  5 in total

1.  Mitochondrial Sirt3 serves as a biomarker for sepsis diagnosis and mortality prediction.

Authors:  Jingjing Liu; Gaosheng Zhou; Rongping Chen; Zewen Tong; Hongmin Zhang; Xiaoting Wang; Dawei Liu
Journal:  Sci Rep       Date:  2022-06-21       Impact factor: 4.996

Review 2.  Timing of vasoactive agents and corticosteroid initiation in septic shock.

Authors:  Mahmoud A Ammar; Abdalla A Ammar; Patrick M Wieruszewski; Brittany D Bissell; Micah T Long; Lauren Albert; Ashish K Khanna; Gretchen L Sacha
Journal:  Ann Intensive Care       Date:  2022-05-30       Impact factor: 10.318

Review 3.  Vasopressor Choice and Timing in Vasodilatory Shock.

Authors:  Patrick M Wieruszewski; Ashish K Khanna
Journal:  Crit Care       Date:  2022-03-22       Impact factor: 9.097

4.  Association of Arterial pH With Hemodynamic Response to Vasopressin in Patients With Septic Shock: An Observational Cohort Study.

Authors:  Seth R Bauer; Gretchen L Sacha; Matthew T Siuba; Simon W Lam; Anita J Reddy; Abhijit Duggal; Vidula Vachharajani
Journal:  Crit Care Explor       Date:  2022-02-08

5.  When to start vasopressin in septic shock: the strategy we propose.

Authors:  Philippe Guerci; Thibaut Belveyre; Nicolas Mongardon; Emmanuel Novy
Journal:  Crit Care       Date:  2022-05-06       Impact factor: 9.097

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.